Clinical AI Evaluation and Workflow Fit
A clinical AI system can perform well on a retrospective dataset and still fail in care. The patients may differ from the development sample, missing records may be more common, the alert may arrive too late, or staff may interpret the output in a way the evaluation never tested.
Clinical AI evaluation must therefore answer a practical question: can the complete intervention support its intended decision, for the intended population, under the conditions in which people will use it? Marketways helps healthcare organisations define that question, build the required evidence and decide whether to redesign, restrict, monitor or proceed with a proposed use.
Define the intended clinical use before choosing a metric
The same model output can support research, prioritise a queue or influence a clinical decision. Each use creates different consequences, time constraints and evidence requirements. A performance score has little meaning until the organisation defines what the system will do.
Marketways maps the intended users, patient population, input data, output, decision, timing and fallback. We also identify what happens when the system cannot produce an answer, when a professional disagrees and when urgent care leaves no time to review the basis of a recommendation.
This definition sets the evaluation boundary. Without it, a team may validate one technical task and deploy a materially different intervention.
Reproduce the population and conditions of use
A dataset can include the required demographic groups while remaining unrepresentative of care. Records collected at a specialist centre may contain more complete histories than those available in routine practice. Equipment, disease prevalence, referral patterns, language and documentation can also vary across locations.
Marketways examines whether evaluation cases reproduce these conditions. We assess prevalence, severity, acquisition process, missingness, equipment, setting and relevant patient characteristics. Where performance differences could create harm, we define subgroup analyses before examining the results.
Small subgroups require particular care. A high or low score based on few cases may reflect sampling variation rather than a dependable difference. We report the uncertainty and identify where further evidence is needed instead of presenting an unstable ranking as a conclusion.
Establish a defensible reference standard
Evaluation requires an expected answer, but clinical ground truth is not always directly observable. Diagnoses may change as new evidence appears, professionals may disagree, and recorded outcomes may reflect the care that patients received after the original decision.
Marketways defines how reference labels are created, who reviews difficult cases and how disagreement is resolved. We distinguish an observed clinical outcome from an expert judgement and preserve uncertainty where neither establishes one incontestable answer.
A weak reference standard places a ceiling on the evaluation. The model may appear wrong because the label is unreliable, or appear correct because it reproduces a systematic error in the records. The evaluation must test the evidence used to judge the system as carefully as it tests the system itself.
Connect discrimination, calibration and thresholds to action
A model may rank higher-risk patients ahead of lower-risk patients while overstating the probability for both groups. Conversely, a well-calibrated model may still fail to separate cases well enough for the intended decision. No single accuracy measure resolves these different questions.
Marketways selects measures that match the proposed use. These may include sensitivity, specificity, predictive value, discrimination and calibration. We then test the thresholds that convert a score into an alert, referral or review.
The threshold determines who receives attention, who waits and how many cases staff must examine. Its value therefore depends on disease prevalence, the consequence of a missed case, the cost of unnecessary escalation and the capacity of the receiving team. A technically attractive threshold is not useful if it overwhelms the clinical response that gives the alert value.
Test the intervention inside the care pathway
Retrospective evaluation asks what the model would have predicted. It does not show whether staff will see the output, understand it, challenge it appropriately or act while an intervention remains possible.
Marketways traces the output through the care pathway. We identify who receives it, what evidence accompanies it, how it changes priority and where responsibility remains. Early testing may use a silent mode, simulation or structured review before the organisation exposes patients and staff to a live intervention.
Prospective evaluation then examines the complete human-AI system. It records acceptance, override, delay, alert burden, disagreement and fallback. The purpose is not to maximise agreement with the model. It is to determine whether the intervention improves the decision without creating new failure modes.
Distinguish an appropriate override from misuse
An override does not automatically prove that a clinician resisted a useful system. The professional may possess relevant evidence that the model could not access. Equally, routine rejection may reveal poor presentation, weak trust or a role conflict that prevents the intervention from functioning.
Marketways reviews overrides with their context and subsequent evidence. We distinguish justified disagreement, misunderstanding, data failure and inappropriate reliance. The analysis can reveal whether the model, interface, training, threshold or operating procedure requires correction.
This learning matters in both directions. Evaluation must detect automation bias, where a user accepts an unsuitable recommendation, as well as disuse, where a user ignores a useful warning.
Evaluate generative and agentic clinical workflows step by step
A generative or Agentic AI system may retrieve records, summarise evidence, call tools, preserve state and route a case. A correct final sentence does not establish that the system used the right patient, respected permissions or completed every required step.
Marketways evaluates the trajectory as well as the output. Tests cover patient and encounter identity, source fidelity, missing information, tool selection, permissions, state, escalation and side effects. We introduce unavailable tools, conflicting records and ambiguous instructions to determine whether the system stops safely or fabricates continuity.
Automated judges may support repeated testing, but they require validation against qualified human review. Material failures should become reproducible regression cases. The organisation can then test whether a system update corrects the failure without weakening another part of the pathway.
Preserve clinical authority and accountable escalation
Technical evaluation cannot assign clinical responsibility. The healthcare organisation must determine which professionals may interpret the output, which decisions require independent review and which conditions require immediate escalation.
Marketways provides statistical, technical and management assurance. We do not make clinical, legal, regulatory or certification decisions. We help clients translate their approved responsibilities into access controls, workflow rules, evidence requirements and incident procedures.
This boundary must exist in the operating design. A disclaimer cannot compensate for an interface that presents uncertain output as a directive or a tool permission that allows an agent to exceed its authorised role.
Monitor changes after deployment
Clinical performance can change even when the model remains unchanged. Patient mix, documentation, equipment, referral practice and treatment can alter the relationship between inputs and outcomes. A software update or workflow redesign can also change how people use the output.
Marketways defines monitoring around the intended use. We track data quality, coverage, calibration, subgroup performance, overrides, alert burden, pathway delay and relevant patient outcomes. Each measure has a review threshold, responsible owner and response.
Monitoring should distinguish random variation from a material change. The organisation also needs a credible route to restrict or suspend the system when evidence no longer supports the approved use.
An early-warning model illustrates the complete evaluation
Suppose a hospital proposes an AI model to identify ward patients at risk of deterioration. A retrospective study reports strong discrimination. However, the system will create value only if it identifies additional patients early enough for the response team to assess them.
The evaluation would first define the population, prediction horizon, alert recipient and available response. It would test calibration and predictive value at the hospital's prevalence, examine relevant subgroups and include the missing observations found in routine records. A silent phase would measure alert timing and volume before staff rely on the output.
A prospective phase would then compare the proposed pathway with current practice. Reviewers would examine missed deterioration, unnecessary escalation, professional overrides, response delays and patient outcomes. Management could decide whether to proceed, adjust the threshold, change the workflow or restrict the use. The headline accuracy would remain evidence, but it would no longer substitute for evidence about clinical usefulness.
How Marketways evaluates clinical AI
Marketways combines AI Governance and Model Risk, Decision Assurance and Model Evaluation and Validation. We define the intended use, assess the population and reference standard, test performance and thresholds, observe human-AI interaction and establish monitoring for changing conditions.
The resulting evaluation tells management whether the evidence supports the proposed use, which limitations require control and which clinical and operational authorities must remain with qualified professionals.